Rhythm Pharmaceuticals (RYTM) Free Cash Flow (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Free Cash Flow data on file, last reported at -$43.8 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 8.7% year-over-year to -$43.8 million in Q1 2026; TTM through Mar 2026 was -$119.6 million, a 4.36% decrease from a year earlier, with the FY2025 full-year figure at -$116.1 million, down 1.93% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$43.8 million, down from -$26.1 million in the prior quarter.
• Over the last five years, Free Cash Flow for RYTM reached as high as -$17.9 million in Q2 2025 and fell as low as -$53.8 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$34.2 million across 5 years, with a median of -$31.9 million in 2025.
• Across the five-year window, Free Cash Flow slumped 60.27% in 2022 and surged 44.4% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$29.4 million in 2022, then rose by 0.18% to -$29.4 million in 2023, then grew by 25.13% to -$22.0 million in 2024, then fell by 18.49% to -$26.1 million in 2025, then slumped by 67.82% to -$43.8 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$43.8 million in Q1 2026, -$26.1 million in Q4 2025, and -$31.9 million in Q3 2025.